Objective To systematically assess credibility and certainty of associations between
cannabis, cannabinoids, and cannabis based medicines and human health, from …

Cannabis potency, defined as the concentration of Δ 9-tetrahydrocannabinol (THC), has
increased internationally, which could increase the risk of adverse health outcomes for …

Background: There is a growing interest in the use of cannabis (and its extracts), as well as
CBD oil (hemp extracts containing cannabidiol), for therapeutic purposes. While there is …

Background Cannabis use is associated with increased risk of later psychotic disorder but
whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of …

The current management of patients with primary psychosis worldwide is often remarkably
stereotyped. In almost all cases an antipsychotic medication is prescribed, with second …

With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

Abstract Purpose of Review We review recent developments on risk factors in
schizophrenia. Recent Findings The way we think about schizophrenia today is profoundly …

The sale of cannabis for adult recreational use has been made legal in nine US states since
2012, and nationally in Uruguay in 2013 and Canada in 2018. We review US research on …

This narrative review represents an output from the International Association for the Study of
Pain's global task force on the use of cannabis, cannabinoids, and cannabis-based …

Background Comorbidity is highly prevalent between substance use disorders (SUDs) and
schizophrenia. This systematic review and meta-analysis estimated prevalence rates of …